{"preliminary_commentary":{"by_channel":{"youtube":10,"x_thread":9,"podcast":4,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04556773\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["trastuzumab deruxtecan","capecitabine"],["trastuzumab deruxtecan","durvalumab","paclitaxel"],["trastuzumab deruxtecan","capivasertib"]],"indication":"HER2-low metastatic breast cancer","name":"DESTINY-Breast08","nct_id":"NCT04556773","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast08-nct04556773. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DB-08","arms":[{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use","label":"Module 1: T-DXd + capecitabine","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use","label":"Module 2: T-DXd + durvalumab + paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use","label":"Module 3: T-DXd + capivasertib","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral","label":"Module 4: T-DXd + anastrozole","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use","label":"Module 5: T-DXd + fulvestrant","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd.","Daiichi Sankyo Company, Limited"],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":138,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a, T-DXd"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol A"],"type":"DRUG"},{"name":"Capivasertib","otherNames":["AZD5363"],"type":"DRUG"},{"name":"Anastrozole","otherNames":["Anastrozol"],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-03","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2023-08-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Occurrence of adverse events (AEs)- Part 1","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 1","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of adverse events (AEs)- Part 2","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 2","timeFrame":"Up to follow-up period, approximately 24 months"}],"references":[],"start_date":{"date":"2020-12-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04556773"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast08-nct04556773"}